Endurant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Endurant Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,992	Closed	-$2.73M	–	61
2022 Q2	$2.73M	Buy	+27,992	New	+$2.58M	0.96%	28
2017 Q1	–	Sell	-11,500	Closed	-$445K	–	94
2016 Q4	$445K	Sell	11,500 -700	-6%	-$31.7K	0.18%	64
2016 Q3	$618K	Sell	12,200 -1,900	-13%	-$94.6K	0.23%	70
2016 Q2	$641K	Buy	14,100 +1,000	+8%	+$46K	0.21%	70
2016 Q1	$518K	Buy	+13,100	New	+$520K	0.17%	68
2015 Q3	–	Sell	-14,900	Closed	-$712K	–	87
2015 Q2	$712K	Buy	+14,900	New	+$632K	0.21%	75

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Endurant Capital Management's NBIX Position: Q3 2022 in Review

Endurant Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 27,992 shares — an estimated $2.73M sold.

Endurant Capital Management first reported a position in NBIX in Q2 2015 and held it in 6 quarters. The position peaked at $2.73M in Q2 2022. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

Endurant Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
Endurant Capital Management sold 27,992 Neurocrine Biosciences shares in Q3 2022, an estimated $2.73M.
Endurant Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 6 quarters.
Endurant Capital Management's Neurocrine Biosciences position peaked at $2.73M in Q2 2022.
466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.